Table 4 HPV16 integration in E2 and viral load as compared to diagnosis and percentage of laminin‐5 immunoreactive cells.

Sample no	Diagnosis	Viral load (E6)*	% Integrated	Copies integrated†	% Laminin‐5	Laminin‐5 stromal
3	Normal	0.13	96	0.12	0	a
4	Normal	0.01	84	0.01	0	a
5	SCC	10.60	35	3.74	100	p
6	CIN3	0.02	100	0.02	0	a
8	SCC	3.77	66	2.49	100	p
9	SCC	16.60	90	14.86	100	p
11	CIN3	0.18	92	0.16	0	a
12	CIN3	0.79	68	0.54	10	p
13	CIN3	0.30	92	0.28	0	a
14	CIN3	0.03	98	0.03	0	a
16	SCC	0.81	95	0.76	60	p
19	CIN3	3.44	80	2.75	0	a
20	CIN3	0.85	90	0.76	0	a
22	CIN3	5.97	57	3.39	0	a
23	SCC	36.40	90	32.87	42	p
25	SCC	1.82	61	1.10	100	p
26	Normal	0.10	96	0.10	0	a
29	Normal	0.08	67	0.05	0	a
30	CIN3	1.37	68	0.94	80	a

HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma.

Laminin‐5 immunoreactive cells in stromal tissue: a, absent; p, present.

*Normalised ratio.

†Number of copies integrated in E2 for one glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) gene.